<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127959</url>
  </required_header>
  <id_info>
    <org_study_id>IAT-0038-04</org_study_id>
    <nct_id>NCT00127959</nct_id>
  </id_info>
  <brief_title>Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection</brief_title>
  <official_title>Virological and Clinical Anti-HBV Efficacy of Tenofovir and Emtricitabine in Antiretroviral Naïve Patients With HIV/HBV co-Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Antiviral Therapy Evaluation Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>International Antiviral Therapy Evaluation Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized multicentre trial of emtricitabine (FTC) versus tenofovir (TDF)/FTC in
      antiretroviral naive subjects with HIV/HBV co-infection over 48 weeks (Clinical Trial A).

      Plus, a 12 week viral kinetic substudy comparing a subgroup of patients on Clinical Trial A
      is being conducted. (Substudy A1)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized multicentre trial of FTC vs TDF/FTC in antiretroviral naive subjects
      with HIV/HBV co-infection over 48 weeks (Clinical Trial A).

      Plus, a 12 week viral kinetic substudy comparing a subgroup of patients on Clinical Trial A
      is being conducted. (Substudy A1)

      Primary Objectives:

        -  To compare the proportion of subjects with HBV DNA levels below the limit of detection
           (&lt;400 copies/ml) by week 48 in each treatment group

      Secondary Objectives:

        -  To evaluate the emergence of HBV resistance at 48 weeks

        -  To compare the proportion of patients with undetectable HBV DNA at weeks 12 and 24 in
           each treatment group

        -  To compare the proportion of patients who achieve HBeAg and HBsAg seroconversion at
           weeks 12, 24 and 48 during the study

        -  To compare changes in ALT from baseline and the rate of hepatic cytolysis (ALT&gt;5x ULN)

        -  To compare suppression of HIV-1 RNA and changes in CD4/CD8 counts over 48 weeks

        -  To compare the effect of therapy on histological changes in the liver and the presence
           of ccc-DNA

      Enrollment:

        -  24 patients in Clinical trial A (of whom 16 enter substudy A1).

      Clinical Trial A:

        -  Patients with HIV/HBV co-infection who are naive to HIV/HBV therapy, have detectable HBV
           viraemia and are willing to start antiretroviral therapy.

      Inclusion Criteria:

        -  Written informed consent

        -  Documented HIV infection

        -  Age 18 – 70 years

        -  HBV DNA &gt; 106 copies/ml

      Randomization:

        -  Arm 1: Zidovudine (AZT), emtricitabine (FTC), efavirenz (EFV)

        -  Arm 2: Tenofovir (TDF), emtricitabine (FTC), efavirenz (EFV)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBV DNA suppression as measured by comparison of area under the curve (AUC) measurements after 48 weeks therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with undetectable HBV DNA in serum</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) seroconversion</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of emergence of lamivudine (LAM)-resistant HBV genotypes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of plasma HIV-RNA (&lt; 50 copies/ml)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4+ /CD8+ cell counts</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of covalently closed circle DNA (cccDNA) on liver biopsy</measure>
  </secondary_outcome>
  <enrollment>24</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hepatitis B</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>emtricitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Documented HIV infection

          -  Age 18 – 70 years

          -  HBV DNA &gt; 10E6 copies/ml

          -  ALT &lt; 10 x ULN (upper limit of normal)

          -  Creatinine &lt;= 2.0mg/dl

          -  Platelet count &gt;= 50,000/mm3

          -  HIV-1 therapy naive

          -  No prior exposure to anti-HBV agents

        Exclusion Criteria:

          -  Hepatitis C viral RNA (CV-RNA) positive or Anti-hepatitis A virus immunoglobulin M
             (HAV IgM) positive

          -  Acute hepatitis (serum ALT &gt; 1000 U/L)

          -  Prior LAM, TDF, or adefovir dipivoxil (ADV) therapy

          -  Active opportunistic infection

          -  Pregnancy or lactation

          -  Other chronic liver disease

          -  Concurrent malignancy requiring cytotoxic chemotherapy

          -  Decompensated or Child’s C cirrhosis

          -  Alfa-fetoprotein (AFP) &gt; 3X ULN (unless negative computed tomography [CT] scan or
             magnetic resonance imaging [MRI] within 3 months of entry date)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joep M.A. Lange, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kiat Ruxrungtham, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIVNAT Bangkok</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Prins, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>NH</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2005</study_first_posted>
  <last_update_submitted>April 23, 2007</last_update_submitted>
  <last_update_submitted_qc>April 23, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2007</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>HBV</keyword>
  <keyword>treatment</keyword>
  <keyword>tenofovir</keyword>
  <keyword>emtricitabine</keyword>
  <keyword>Treatment Naive</keyword>
  <keyword>HIV-1 infection</keyword>
  <keyword>Hepatitis B virus infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

